You are here
Home > Helsinn Group

Helsinn Advanced Synthesis opens its largest dedicated Anticancer bay

Helsinn Advanced Synthesis opens its largest dedicated Anticancer bay Biasca, Switzerland, July 30, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, announces that its manufacturing subsidiary, Helsinn Advanced Synthesis SA (HAS), which develops and manufactures Active Pharmaceutical Ingredients (APIs), cGMP Advanced Intermediates, High Potency APIs (HPAPIs) […]

Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America

Lugano, Switzerland, São Paulo, Brazil, and Buenos Aires, Argentina, September 2, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, together with Blanver Farmoquímica e Farmacêutica S.A., a Brazilian company focused on innovative products with high quality medicines and active pharmaceutical ingredients, committed to expand patient access, and Laboratorio Varifarma SA, […]

Helsinn nominated as a Swiss Biotech Success Story 2019/2020 by the Swiss Biotech Association

Helsinn nominated as a Swiss Biotech Success Story 2019/2020 by the Swiss Biotech Association Switzerland, May 7, 2019: Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that it is one of the companies to have been nominated as one of the Swiss Biotech Association’s Biotech Success Stories for the […]

Helsinn initiates two new global Phase III studies with anamorelin

Helsinn initiates two new global Phase III studies with anamorelin Helsinn committed to anamorelin which is being evaluated for weight loss and anorexia in patients with advanced non small cell lung cancer (NSCLC) and cachexia ONO has submitted application for manufacturing and marketing approval of anamorelin in Japan LUGANO, Switzerland, March 7, 2019: Helsinn Group, […]

Top